$86.3 Million

Sera Prognostics, Inc.

Initial Public Offering

Bookrunner, July 2021

Sera Prognostics, Inc. (“Sera Prognostics” or the “Company”) is a women’s health company leveraging its proprietary proteomics and bioinformatics platform to discover, develop and commercialize clinically meaningful and economically impactful biomarker tests, with an initial focus on improving pregnancy outcomes. Sera’s vision is to delivery pivotal and actionable information to pregnant women, their physicians and healthcare payers to improve maternal and neonatal health and reduce healthcare costs.